WO1998058663A1 - Influence d'enzymes proteolytiques sur des cytokines - Google Patents

Influence d'enzymes proteolytiques sur des cytokines Download PDF

Info

Publication number
WO1998058663A1
WO1998058663A1 PCT/EP1998/003765 EP9803765W WO9858663A1 WO 1998058663 A1 WO1998058663 A1 WO 1998058663A1 EP 9803765 W EP9803765 W EP 9803765W WO 9858663 A1 WO9858663 A1 WO 9858663A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzymes
cytokines
trypsin
cells
enzyme
Prior art date
Application number
PCT/EP1998/003765
Other languages
German (de)
English (en)
Inventor
Gerhard Stauder
Karl Ransberger
Original Assignee
Mucos Pharma Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucos Pharma Gmbh & Co. filed Critical Mucos Pharma Gmbh & Co.
Priority to EP98934985A priority Critical patent/EP0918537A1/fr
Publication of WO1998058663A1 publication Critical patent/WO1998058663A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates to a method for influencing cytokines by proteolytic enzymes and the use of proteolytic enzymes for influencing cytokines.
  • cytokines are important metabolic substances in triggering various disease states. Cytokines are small proteins with molecular weights of 8,000 to 30,000, with each cytokine having its own amino acid sequence and cell surface receptors. They are made from a variety of different cell types and act on almost every tissue and organ system. The names given to the various cytokines do not follow a logical system, but rather correspond to their biological properties. IL-1 and TNF (tumor necrosis factor) are the primary pro-inflammatory cytokines, and moreover, these two cytokines act in a synergistic manner in inducing inflammation, shock and death.
  • interleukin-2 receptor e.g. interleukin-2 is the natural ligand.
  • Other cytokines are also ligands of the surface molecules and are therefore influenced by them.
  • Certain infections or cancers result in a shift in various subpopulations of lymphocytes, granulocytes and monocytes in homeostasis. Normally the organism is able to restore the distributional equilibria of the subpopulations in the process of recovery.
  • the present invention was therefore based on the technical problem of specifying a method for influencing cytokines.
  • the use of at least one proteolytic enzyme and optionally rutoside is provided for influencing cytokines.
  • the immunoglobulins modulated by the proteolytic enzyme or enzymes are distinguished by the fact that their binding capacity for the complement component C1q is reduced. This applies to natural C1 q-binding immunoglobulins (subclasses IgG1, IgG2, IgG3, IgM and partly IgA).
  • the changed C1 q binding capacity is - without being bound by any theory - probably caused by a change in the conformation of the C H 2 domain due to the action of the enzyme.
  • the conformational change can either be caused directly by an enzyme-induced change in the C H 2 domain, or the proteolytic enzymes cause a structural change in the regions adjacent to the C H 2 domain, and these changes influence the conformation of the C H 2 domain. Domain.
  • trypsin, bromelain, papain and optionally rutin or a combination thereof is used as the proteolytic enzyme.
  • the enzymes used according to the invention can be isolated inexpensively from the following raw materials.
  • Bromelain is a proteolytically active enzyme from the pineapple juice and can also be isolated from ripe fruit.
  • Papain is a proteolytic enzyme obtained from the milk sap of the immature, meaty fruits of the Carica Papaya melon tree.
  • Pure papain is a crystalline polypeptide with an MG. from 23350 consisting of a chain of 212 amino acid residues with 4 disulfide bridges; Sequence and spatial structure are known.
  • Papain is used in many different ways: due to its protein-splitting properties as "meat tenderizer” or “short salt”, for clarifying beer, for bread and hard biscuit production, in leather preparation, in the textile industry for degassing silk and for preventing wool matting, in the tobacco industry for quality improvement, for the recovery of silver from used photographic material, furthermore in bacteriology for the extraction of peptone.
  • papain is already used to support enzymatic digestion, for enzymatic wound cleaning and as an additive to denture cleaning agents.
  • papain preparations are also available bound to plastic polymers or agarose. Papain has also been used as a catalyst for the synthesis of oligopeptides.
  • Trypsin is a proteolytic enzyme that is also formed in the pancreas and is already used therapeutically in conjunction with other enzymes. It belongs to the serine proteinases. Crystalline trypsin has a MW of approx. 23300, is soluble in water but not in alcohol, has an optimum activity at pH 7-9 and cleaves peptide chains specifically on the carboxy side of the basic amino acid residues L-lysine and L-arginine. The spatial structure of the 223 amino acid trypsin is known.
  • Rutoside can also be added to the medication.
  • Rutoside is a glycoside that belongs to the flavonoids. The combined use of 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin per dose unit is particularly effective.
  • a combination of 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H 2 O is very particularly preferred.
  • a combination of 48 mg trypsin, 90 mg bromelain and 100 mg rutoside x 3H 2 0 is used.
  • 10 to 100 mg, particularly preferably 100 mg of rutoside x 3 H 2 0 are used per dose unit.
  • the medicament can furthermore contain all customary auxiliaries and / or carriers.
  • Auxiliaries and carriers include e.g. Lactose, magnesium stearate, stearic acid, talc, methacrylic acid, copolymer type A, Shellack, Makrogol 6000, di-butyl phthalate, vanillin, titanium dioxide, white clay, polyindone, yellow wax and camauba wax.
  • the invention further relates to the additional use of ⁇ 2 -Macroglobulin ( ⁇ 2 -M).
  • ⁇ 2 -M is one of the most important inhibitors of proteinases. 2 -M reacts with a variety of endopeptidases. The reaction of ⁇ 2 -M with the respective proteinase usually takes place in such a way that ⁇ 2 -M is subject to a change in conformation after it has come into contact with the proteinase and then holds it in the molecule. The enzyme inhibition is based on steric hindrance, although the active center of the enzyme remains functional.
  • ⁇ 2 -M contributes to immunomodulation by influencing cytokines.
  • the invention further relates to a method for influencing cytokines, the cytokines being brought into contact with one or more proteolytic enzymes and optionally rutoside.
  • the RPMI 1640 cell culture medium was used with the following additives: NaHC03 ( biochrom, 2 g / 1); L-glutamine (biochrom, 2 mM), Na pyruvate (biochrom,
  • phythaemagglutinin M biologicalchrome, 5 ⁇ g / ml
  • ⁇ -interferon 100 U / ml
  • Freshly isolated, human, peripheral, mononuclear blood cells were used as targets for the enzymes to be examined. After the usual isolation using Ficoll, the cells were washed several times and used fresh in the experiments. Neutrophil granulocytes were also isolated from fresh citrate blood. Here, the lymphocytes / monocytes were separated using a 2-stage Ficoll gradient.
  • Monoclonal antibodies were used for the specific recognition of the surface structures of the leukocytes. These recognize on the corresponding each have a defined epitope, which occurs only once in the structure of the antigens examined by us.
  • Overview 1 shows the surface markers examined, the monoclonal antibodies and the analyzed target cells.
  • the freshly isolated and prepared cells were incubated with the enzymes bromelain, papain and trypsin (pharmaceutical ingredients from Mucos) with the concentrations given in the legends of the tables and figures.
  • bromelain papain: trypsin, based on 40 ⁇ g / ml, “BPT”).
  • Three enzyme concentrations (40, 10, 2.5 ⁇ g / ml) were examined. The incubation took place in serum-free medium at 37 ° C.
  • proteases were set up immediately before the incubations. 0.01% sodium acid was contained in the cell culture media. This addition prevents the cells from during the incubation process or the washing process. would express receptor molecules again. After washing out the cell culture medium, the cells can be reactivated (not demonstrated).
  • a corresponding fluorescence-conjugated isotype control was carried out for each subclass of the monoclonal antibodies.
  • This is mouse immunoglobulin, with which the capacity of the non-specific binding of the target cells is determined by flow cytometry.
  • the evaluation and analysis of the data was carried out independently of the measurement process on the flow cytometer using device-specific software.
  • the histograms of the controls ie the untreated cell samples, were compared with the histograms of the enzyme-treated cells.
  • the raw representation comprises an optically spectacular, but relatively confusing histogram, in which various individual measurements are shown superimposed on one another.
  • the effect of the enzymes can be made optically transparent compared to the reference. For these investigations, it is not the percentage of a subpopulation of the total leukocyte population that is the measured variable, but rather the relative receptor density, which is shown as the fluorescence intensity.
  • data can be derived which reflect the relative fluorescence intensity of the individual measurement. This is a measure of the relative receptor or surface molecule density in a measured cell population.
  • the bar graphs show the media of relative fluorescence in a logarithmic representation. Compared to the reference, the reduction in the density of the respective surface molecule as a function of the enzyme concentration can be represented.
  • the tables contain the data from independent experiments.
  • the donor numbers are only valid for the respective table and cannot be transferred to other tables. If, for example, a value of 40% is given in the table, this means that in this antigen 40% of all surface molecules are changed by the enzyme in such a way that the specific monoclonal antibody no longer recognizes its epitope. If no reduction is observed, the value "0" appears in the tables. The percentage given thus expresses the enzyme performance against the individual antigens. Values up to 20% are not considered relevant in individual cases.
  • the data were evaluated using non-linear regression.
  • the median of the fluorescence intensity versus the enzyme concentration used and the reference are correlated with one another, and from this the amount of enzyme can be calculated which leads to a 50% reduction in the relative fluorescence intensity or in the structure of the changed receptor density.
  • Figure I CD2 modulation by proteases; The median of the relative fluorescence intensity is given; Target cells: lymphocytes.
  • the positive control (reference) are untreated cells that were incubated with the monoclonal antibody specific for CD2.
  • the negative controls are untreated cells incubated with the antibody isotype. The incubation time with the enzymes was 60 min.
  • the data from donor 1 (see Tab. 1) are shown as the mean of double determinations and standard deviation.
  • FIG. 2 CD4 (epitope Leu3a) modulation by proteases; The median of the relative fluorescence intensity is given; Target cells: lymphocytes.
  • the positive control (reference) are untreated cells that were incubated with the monoclonal antibody specific for CD4.
  • the negative controls are untreated cells incubated with the antibody isotype. The incubation time with the enzymes was 60 min.
  • the data from donor 2 (see Tab. 2) are shown as the mean of double determinations and standard deviation.
  • Figure 3 CD4 (Epitope OKT4 and Leu3a) modulation by trypsin; The median of the relative fluorescence intensity is given; Target cells: lymphocytes.
  • the positive control (reference) are untreated cells that were incubated with the monoclonal antibody specific for CD4.
  • the negative controls are untreated cells incubated with the antibody isotype. The incubation on time with the enzymes was 60 min.
  • the data from a donor (see Table 3) are shown as the mean of double determinations and standard deviation.
  • Figure 4 CD25 modulation by proteases; The median of the relative fluorescence intensity is given; Target cells: PHA blasts.
  • the positive control (reference) are untreated cells that were incubated with the monoclonal antibody specific for CD25.
  • the negative controls are untreated cells incubated with the antibody isotype. The incubation time with the enzymes was 60 min.
  • the data from donor 1 are shown as the mean of duplicate determinations and standard deviation.
  • Figure 5 Reduction of the Leu3a antigen density by trypsin. Freshly isolated human peripheral, mononuclear blood cells were incubated with trypsin in the serum-free medium, then washed and labeled with the monoclonal antibody anti-Leu3a. The reduction in the relative fluorescence density of CD4 in the lymphocyte population is the measure of enzyme activity. The half-effect concentration of trypsin compared to the epitope Leu3a of CD4 is calculated using the fitted curve.
  • Table 1 CD2 modulation by proteases; Target cells: lymphocytes. The percentage reduction in the median of the relative fluorescence intensity, which is a measure of the enzyme performance, is given. The incubation time with the enzymes was 60 min. The results of three experiments with cells from three different donors are shown.
  • CD4 epitopope Leu3a modulation by proteases
  • Target cells lymphocytes.
  • the percentage reduction in the median of the relative fluorescence intensity, which is a measure of the enzyme performance, is given.
  • the incubation time with the enzymes was 60 min. The results of two experiments with cells from two different donors are shown.
  • Table 3 Modulation of the CD4 epitopes Leu3a and OKT4 by trypsin; Target cells: lymphocytes. The percentage reduction in the median of the relative fluorescence intensity, which is a measure of the enzyme performance, is given. The incubation time with the enzymes was 60 min. The data from a donor are shown. Enzyme epitope 40 ⁇ g / ml 20 ⁇ g / ml 10 ⁇ g / ml
  • Table 4 CD25 modulation by proteases; Target cells: lymphocytes, monocytes, NK cells. The percentage reduction in the median of the relative fluorescence intensity, which is a measure of the enzyme performance, is given. The incubation time with the enzymes was 60 min. The results of two experiments with cells from two different donors are shown. The cells were mitogen stimulated for 3 days prior to the experiment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'au moins une enzyme protéolytique pour influer sur des cytokines. On utilise de préférence la trypsine, la bromélaïne et la papaïne comme enzymes protéolytiques. On peut également utiliser la rutoside.
PCT/EP1998/003765 1997-06-20 1998-06-19 Influence d'enzymes proteolytiques sur des cytokines WO1998058663A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98934985A EP0918537A1 (fr) 1997-06-20 1998-06-19 Influence d'enzymes proteolytiques sur des cytokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19726255A DE19726255C2 (de) 1997-06-20 1997-06-20 Beeinflussung von Cytokinen durch proteolytische Enzyme und Rutosid
DE19726255.4 1997-06-20

Publications (1)

Publication Number Publication Date
WO1998058663A1 true WO1998058663A1 (fr) 1998-12-30

Family

ID=7833164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003765 WO1998058663A1 (fr) 1997-06-20 1998-06-19 Influence d'enzymes proteolytiques sur des cytokines

Country Status (3)

Country Link
EP (1) EP0918537A1 (fr)
DE (1) DE19726255C2 (fr)
WO (1) WO1998058663A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369053A (en) * 2000-09-18 2002-05-22 Shigemi Fujisaki Treatment of AIDS, hepatitis B, hepatitis C and influenza using metalloendopeptidase-F optionally in conjunction with one or more other proteases
US6987129B2 (en) 2001-03-06 2006-01-17 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
WO2008080194A1 (fr) * 2006-12-29 2008-07-10 The University Of Queensland Compositions analgésiques et leurs utilisations
US8822509B2 (en) 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19847114A1 (de) * 1998-10-13 2000-04-20 Mucos Pharma Gmbh & Co Beeinflussung von hyperaktiven T-Zellen durch proteolytische Enzyme
DE10018980A1 (de) * 2000-04-17 2001-11-08 Mucos Pharma Gmbh & Co Prophylaxe und Therapie von Diabetes mellitus I mit Hilfe proteolytischer Enzyme

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5978122A (ja) * 1982-10-27 1984-05-04 Ajinomoto Co Inc コロニ−刺激因子の製造法
EP0421023A1 (fr) * 1989-10-06 1991-04-10 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Enzymes catabolisantes pour l'induction du facteur de nécrose tumorale (TNF)
DE4130221A1 (de) * 1991-09-11 1993-03-18 Mucos Pharma Gmbh Verwendung von proteolytischen enzymen zur herstellung eines medikaments zur behandlung einer krankheit, an deren entstehung proteine mit einer c(pfeil abwaerts)h(pfeil abwaerts)2-domaene beteiligt sind
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
DE4336343A1 (de) * 1993-10-25 1995-04-27 Mucos Pharma Gmbh & Co Verwendung von hydrolytischen Enzymen zur Abortprophylaxe bei Schwangeren mit idiopathischem Abortus habitualis in der Anamnese
WO1996000082A1 (fr) * 1994-06-24 1996-01-04 Cortecs Limited Utilisation medicale de la bromelaine
WO1997024138A2 (fr) * 1995-12-29 1997-07-10 Cortecs (Uk) Limited Utilisation medicale de proteases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5978122A (ja) * 1982-10-27 1984-05-04 Ajinomoto Co Inc コロニ−刺激因子の製造法
EP0421023A1 (fr) * 1989-10-06 1991-04-10 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Enzymes catabolisantes pour l'induction du facteur de nécrose tumorale (TNF)
DE4130221A1 (de) * 1991-09-11 1993-03-18 Mucos Pharma Gmbh Verwendung von proteolytischen enzymen zur herstellung eines medikaments zur behandlung einer krankheit, an deren entstehung proteine mit einer c(pfeil abwaerts)h(pfeil abwaerts)2-domaene beteiligt sind
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
DE4336343A1 (de) * 1993-10-25 1995-04-27 Mucos Pharma Gmbh & Co Verwendung von hydrolytischen Enzymen zur Abortprophylaxe bei Schwangeren mit idiopathischem Abortus habitualis in der Anamnese
WO1996000082A1 (fr) * 1994-06-24 1996-01-04 Cortecs Limited Utilisation medicale de la bromelaine
WO1997024138A2 (fr) * 1995-12-29 1997-07-10 Cortecs (Uk) Limited Utilisation medicale de proteases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 008, no. 184 (C - 239) 23 August 1984 (1984-08-23) *
STAUDER G. ET AL: "Use of oral enzymes in multiple sclerosis: phenotyping of peripheral blood lymphocytes from MS patients under long-term treatment with orally administered hydrolytic enzymes", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, vol. xiii, no. 3/4, 1997, pages 135 - 137, XP002081005 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369053A (en) * 2000-09-18 2002-05-22 Shigemi Fujisaki Treatment of AIDS, hepatitis B, hepatitis C and influenza using metalloendopeptidase-F optionally in conjunction with one or more other proteases
US6987129B2 (en) 2001-03-06 2006-01-17 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
WO2008080194A1 (fr) * 2006-12-29 2008-07-10 The University Of Queensland Compositions analgésiques et leurs utilisations
US8822509B2 (en) 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor
US9994534B2 (en) 2006-12-29 2018-06-12 The University Of Queensland Pain-relieving compositions and uses therefor

Also Published As

Publication number Publication date
DE19726255C2 (de) 2000-03-16
DE19726255A1 (de) 1998-12-24
EP0918537A1 (fr) 1999-06-02

Similar Documents

Publication Publication Date Title
DE3686927T2 (de) Neovaskularisierungsinhibitoren und deren herstellung.
DE3019847C2 (de) Verfahren zur Herstellung von Humaninterferon
EP0952213A2 (fr) Procédé pour induire une réponse immunitaire par l'intermédiaire de cellules NK
DE3750235T2 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
DE69006676T2 (de) Tripeptidverbindungen und ihre pharmazeutische Anwendung als Immunmodulatoren.
DE2635065A1 (de) Verfahren zur halbkontinuierlichen behandlung von gesamtblut
DE19726255C2 (de) Beeinflussung von Cytokinen durch proteolytische Enzyme und Rutosid
DE4242902A1 (de) Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie
EP0421023B1 (fr) Enzymes catabolisantes pour l'induction du facteur de nécrose tumorale (TNF)
DE2645993A1 (de) Mittel gegen myeloische leukaemie und sein herstellungsverfahren
DE69020157T2 (de) Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren.
DE69220078T2 (de) Verfahren und zusammensetzung zur bestimmung der immunologischen aktivitaet von bioaktiven substanzen
DE69330960T2 (de) Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
EP0607593B1 (fr) Procédé d'ontention de cultures cellulaires avec un taux amélioré de cytokines autogènes
DE69131202T2 (de) Die Verwendung von IL-4 und TNF zur Herstellung eines Medikaments zur Behandlung von Krebszellen
EP0920332B1 (fr) Combinaison des enzymes proteolytiques trypsin, bromelain et papain pour traiter la glomerulonephrite
DE19726244C2 (de) Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
DE69636790T2 (de) Interferon-beta gegen knochenerkrankungen
DE19726251C2 (de) Verwendung proteolytischer Enzyme zur Behandlung von Uveitis
DE19726248C2 (de) Verwendung proteolytischer Enzyme und Rutosid zur Behandlung von septischem Schock
DE69233337T2 (de) Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen
EP1121146B1 (fr) Utilisation d'enzymes proteolytiques pour influer sur des lymphocytes t hyperactifs
DE19609261C2 (de) Arzneimittel zur Vorbeugung gegen und Behandlung der durch Chemotherapie von Tumorerkrankungen bedingten Myelosuppression
EP0815253A1 (fr) Melange de modulateurs d'immunite multifactoriel, son procede de fabrication et medicaments renfermant ces modulateurs
EP0889053A2 (fr) Utilisations des préparations à base de BK-RiV, procédé de leur production, et les protéines contenues dans celles-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998934985

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998934985

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09242585

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998934985

Country of ref document: EP